文献速递淋巴瘤

埃普可妥单抗对比化学免疫治疗、莫妥珠单抗或奥妥珠单抗在滤泡性淋巴瘤中的间接比较

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

该匹配调整间接比较利用EPCORE NHL-1滤泡性淋巴瘤队列的个体患者数据、SCHOLAR-5汇总数据及GO29781和ELM-2的聚合数据,比较埃普可妥单抗与标准治疗、莫妥珠单抗或奥妥珠单抗的疗效与安全性。结果显示埃普可妥单抗较标准治疗/化学免疫治疗显著提高缓解率,较莫妥珠单抗和奥妥珠单抗显示数值更高的总缓解率及更好的细胞因子释放综合征和免疫效应细胞相关神经毒性综合征安全性。

要点

  • 埃普可妥单抗较标准治疗/化学免疫治疗显著提高ORR(90.9% vs 56.8%)和CR率(73.7% vs 32.0%)。
  • 埃普可妥单抗较莫妥珠单抗ORR数值更高(90.9% vs 80.0%)但未达统计学显著(P=.067)。
  • 埃普可妥单抗组无≥3级CRS或任何级别ICANS事件,低于莫妥珠单抗和奥妥珠单抗组。

核心结论

  • 在复发或难治性滤泡性淋巴瘤患者中,埃普可妥单抗较标准治疗/化学免疫治疗显示显著更优的缓解率和生存结局。
  • 埃普可妥单抗较莫妥珠单抗或奥妥珠单抗显示临床相关、数值更高的ORR,并在≥3级CRS和ICANS方面显示更好的安全性。

研究设计与样本

  • 匹配调整间接比较,使用EPCORE NHL-1滤泡性淋巴瘤队列的个体患者数据、SCHOLAR-5的汇总数据(标准治疗,主要为化学免疫治疗)以及GO29781(莫妥珠单抗)和ELM-2(奥妥珠单抗)的聚合数据。
  • 采用倾向评分权重对关键基线特征进行匹配调整。

主要发现

  • 埃普可妥单抗对比标准治疗/化学免疫治疗:ORR为90.9% vs 56.8%(P<.001),CR率为73.7% vs 32.0%(P<.001)。
  • 埃普可妥单抗对比莫妥珠单抗:ORR为90.9% vs 80.0%(P=.067),CR率为72.8% vs 60.0%(P=.159)。
  • 埃普可妥单抗对比奥妥珠单抗:ORR为91.5% vs 80.5%(P=.026),CR率为67.5% vs 73.4%(P=.428)。
  • 埃普可妥单抗组无≥3级CRS或任何级别ICANS事件;莫妥珠单抗组≥3级CRS为2.2%、ICANS为4.4%;奥妥珠单抗组≥3级CRS为3.9%、ICANS为0.8%(P<.001)。

关键数值与推荐

  • 埃普可妥单抗对比标准治疗/化学免疫治疗:ORR 90.9% vs 56.8%(P<.001);CR率73.7% vs 32.0%(P<.001)。
  • 埃普可妥单抗对比莫妥珠单抗:ORR 90.9% vs 80.0%(P=.067);CR率72.8% vs 60.0%(P=.159)。
  • 埃普可妥单抗对比奥妥珠单抗:ORR 91.5% vs 80.5%(P=.026);CR率67.5% vs 73.4%(P=.428)。
  • 安全性:埃普可妥单抗无≥3级CRS或任何级别ICANS;莫妥珠单抗≥3级CRS 2.2%、ICANS 4.4%;奥妥珠单抗≥3级CRS 3.9%、ICANS 0.8%(P<.001)。

临床怎么用

  • 埃普可妥单抗为皮下给药方案,在复发或难治性滤泡性淋巴瘤患者中较标准治疗/化学免疫治疗显示显著更优的缓解率和生存结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This matching-adjusted indirect comparison evaluated the efficacy of epcoritamab vs standard of care (SOC), mosunetuzumab, or odronextamab, and assessed safety vs mosunetuzumab and odronextamab. Individual patient-level data from the EPCORE NHL-1 follicular lymphoma (FL) cohort for epcoritamab were used with pooled data from SCHOLAR-5 for SOC (mostly chemoimmunotherapy [CIT]), and aggregate data from GO29781 for mosunetuzumab and ELM-2 for odronextamab. Trial populations were match-adjusted using propensity score weights for key baseline characteristics. Compared with SOC/CIT, epcoritamab provided significantly higher response rates (overall response rate [ORR], 90.9% vs 56.8%; P < .001; complete response [CR] rate, 73.7% vs 32.0%; P < .001). Epcoritamab showed numerically higher ORR (90.9% vs 80.0%; P = .067) and CR rate (72.8% vs 60.0%; P = .159) vs mosunetuzumab. Epcoritamab provided significantly higher ORR (91.5% vs 80.5%; P = .026) and numerically lower CR rate (67.5% vs 73.4%; P = .428) vs odronextamab. Epcoritamab did not have any grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS; any grade) events compared with CRS (grade ≥3) in 2.2% and 3.9% and ICANS in 4.4% and 0.8% of patients treated with mosunetuzumab and odronextamab, respectively (P < .001). In addition to being a convenient subcutaneous option, epcoritamab showed significantly superior response rates and survival outcomes vs SOC/CIT among patients with relapsed or refractory FL after ≥2 systemic therapies. Epcoritamab also exhibited clinically relevant, numerically higher ORRs and demonstrated improved safety for CRS (grade ≥3) and ICANS vs mosunetuzumab or odronextamab. These trials were registered at www.ClinicalTrials.gov as #NCT03625037, #NCT02500407, and #NCT03888105.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Danilov AV, Kambhampati Thiruvengadam S, Linton K, et al. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Adv. 2025. PMID: 40472301. doi:10.1182/bloodadvances.2024015274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。